

pUNO1-hSTING-N200

Expression vector containing N200 isoform human STING (I200N) open reading frame

Catalog code: puno1-hsting-n200

<https://www.invivogen.com/hsting-n200>

For research use only

Version 19K10-MM

PRODUCT INFORMATION

Contents

- 20 µg of lyophilized plasmid DNA
- 2 x 1 ml blasticidin at 10 mg/ml

Storage and Stability

- Product is shipped at room temperature.
- Lyophilized DNA should be stored at -20°C.
- Resuspended DNA should be stored at -20°C and is stable at least for 1 year.
- Store blasticidin at 4°C or -20°C.*

*The expiry date is specified on the product label.

Quality control

- Plasmid construct has been confirmed by restriction analysis and full-length open reading frame (ORF) sequencing.
- Plasmid DNA was purified by ion exchange chromatography.

GENERAL PRODUCT USE

- **Subclone gene into another vector.** Two unique restriction sites flank the gene, allowing convenient excision. The 5' site is BspEI which is compatible with AgeI, XmaI, NgoMIV and SgrAI. The 3' site is NheI which is compatible with XbaI, SpeI, and AvrII.
- **Stable gene expression in mammalian cells.** pUNO1 plasmids can be used directly in transfection experiments both *in vitro* and *in vivo*. pUNO1 plasmids contain the blasticidin-resistance gene (*bsr*) driven by the CMV promoter/enhancer in tandem with the bacterial EM7 promoter. This allows the amplification of the plasmid in *E. coli*, as well as the selection of stable clones in mammalian cells using the same selective antibiotic. pUNO1 allows high levels of expression and secretion of the gene product.

METHODS

Plasmid resuspension

Quickly spin the tube containing the lyophilized plasmid to pellet the DNA. To obtain a plasmid solution at 1 µg/µl, resuspend the DNA in 20 µl of sterile water. Store resuspended plasmid at -20°C.

Plasmid amplification and cloning

Plasmid amplification and cloning can be performed in *E. coli* GT116 or other commonly used laboratory *E. coli* strains, such as DH5α.

Blasticidin usage

Blasticidin should be used at 25-100 µg/ml in bacteria and 1-30 µg/ml in mammalian cells. Blasticidin is supplied as a 10 mg/ml colorless solution in HEPES buffer.

PLASMID FEATURES

- **Bsr (blasticidin resistance gene):** The *bsr* gene from *Bacillus cereus* encodes a deaminase that confers resistance to the antibiotic blasticidin. The *bsr* gene is driven by the CMV promoter/enhancer in tandem with the bacterial EM7 promoter. Therefore, blasticidin can be used to select stable mammalian cells transfectants and *E. coli* transformants.
- **CMV promoter & enhancer** drives the expression of the blasticidin resistance in mammalian cells.

• Human STING-N200

ORF size: 1140 bp

Cloning fragment size: 1181 bp

STING (stimulator of interferon genes; also known as TMEM173, MITA, MPYS, and ERIS) is essential for the IFN response to microbial or self-DNA, and acts as a direct sensor of cyclic dinucleotides (CDNs). CDNs are important messengers in bacteria, affecting numerous responses of the prokaryotic cell, but also in mammalian cells, acting as agonists of the innate immune response. Studies have revealed that STING variation can affect CDN recognition and signal transduction. The hSTING-N200 isoform harbors a missense mutation (I200N) equivalent to I199N mutation found in the *Goldenticket* (*Gt*) mouse strain^{1,2}. Residue I200 is buried in the interior of the STING protomer. The I200N mutation results in a null-phenotype with no detectable STING activity¹.

• **EF-1α/HTLV hybrid promoter** is a composite promoter comprised of the Elongation Factor-1α (EF-1α) core promoter³ and the 5' untranslated region of the Human T-Cell Leukemia Virus (HTLV). EF-1α utilizes a type 2 promoter that encodes for a «house keeping» gene. It is expressed at high levels in all cell cycles and lower levels during G0 phase. The promoter is also non-tissue specific; it is highly expressed in all cell types. The R segment and part of the U5 sequence (R-U5') of the HTLV Type 1 Long Terminal Repeat⁴ has been coupled to the EF-1α promoter to enhance stability of DNA and RNA. This modification not only increases steady state transcription, but also significantly increases translation efficiency possibly through mRNA stabilization.

• **SV40 pAn:** The Simian Virus 40 late polyadenylation signal enables efficient cleavage and polyadenylation reactions, resulting in high levels of steady-state mRNA⁵.

• **pMB1 ori** is a minimal *E. coli* origin of replication to limit vector size, but with the same activity as the longer Ori.

• **Human beta-Globin polyA** is a strong polyadenylation (pAn) signal placed downstream of *bsr*. The use of beta-globin pAn minimizes interference⁶ and possible recombination events with the SV40 polyadenylation signal.

1. Yin Q. *et al.*, 2012. Cyclic di-GMP sensing via the innate immune signaling protein STING. *Mol Cell* 46(6):735-45. 2. Sauer JD. *et al.*, 2011. The N-ethyl-N-nitrosourea-induced Goldenticket mouse mutant reveals an essential function of Sting in the *in vivo* interferon response to *Listeria monocytogenes* and cyclic dinucleotides. *Infect Immun* 79(2):688-94. 3. Kim D. *et al.*, 1990. Use of the human elongation factor 1α promoter as a versatile and efficient expression system. *Gene* 91(2):217-23. 4. Takebe Y. *et al.*, 1988. SR alpha promoter: an efficient and versatile mammalian cDNA expression system composed of the simian virus 40 early promoter and the R-U5 segment of human T-cell leukemia virus type 1 long terminal repeat. *Mol Cell Biol* 8(1):466-72. 5. Carswell S. & Alwine J., 1989. Efficiency of utilization of the simian virus 40 late polyadenylation site: effects of upstream sequences. *Mol Cell Biol* 9(10):4248-58. 6. Yu J. & Russell J., 2001. Structural and functional analysis of an mRNP complex that mediates the high stability of human β-globin mRNA. *Mol Cell Biol* 21(17):5879-88.

RELATED PRODUCTS

Product	Description	Cat. Code
Blasticidin	Selection antibiotic	ant-bl-1
ChemiComp GT116	Competent <i>E. coli</i>	gt116-11

TECHNICAL SUPPORT

InvivoGen USA (Toll-Free): 888-457-5873


InvivoGen USA (International): +1 (858) 457-5873

InvivoGen Europe: +33 (0) 5-62-71-69-39

InvivoGen Hong Kong: +852 3622-3480

E-mail: info@invivogen.com

 **InvivoGen**
www.invivogen.com



125

PvuI (7) MfeI (82)
SgfI (6)
1 GGATCTGCGATCGCTCCGGTCCCGTCAGTGGGCAGAGCGCACATCGCCACAGTCCCCGAGAAGTTGGGGGAGGGGTCGGCAATTGAACGGGTGCCTA

101 GAGAAGGTGGCGCGGGTAAACTGGGAAAGTGTCTGTACTGGCTCCGCCCTTTTCCCGAGGGTGGGGGAGAACCCTATATAAGTGCAGTAGTCGCC

Psp1406I (203) HindIII (245) Bsu36I (291)
201 GTGAACGTTCTTTTTTCGCAACGGGTTTCCGCCAGAACACAGCTGAAGCTTCGAGGGCTCGCATCTCTCTTCACGCGCCCGCCCTACCTGAGGGC

301 GCCATCCACGCGGTTGAGTCGCGTCTGCGCCCTCCCGCTGTGGTGCCTCCTGAAGTCCGCTCCGCGCTAGGTAAGTTTAAAGCTCAGGTCGAGACC

NgoMI (441) NaeI (441)
401 GGGCCTTTGTCCGGCGCTCCCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCAGCTTTGCTGACCCTGCTTGCTCAACTCTACGCTTTGTTCTGTTT

BspEI (558)
501 TCTGTTCTGCGCGCTTACAGATCCAAGCTGTGACCGGCGCTACCTGAGATCACCGGCTCCGGACAGCATGCCCACTCCAGCCTGCATCCATCCATCCC
1 M P H S S L H P S I P

Bsp120I (617)
601 GTGTCCAGGGGTACGGGGCCAGAAAGGAGCAGCTTGGTTCTGCTGAGTGCCTGCCTGGTACCCTTTGGGGCTAGGAGAGCCACCAGAGCACACTCTC
11 C P R G H G A Q K A A L V L L S A C L V T L W G L G E P P E H T L

SexAI (704) Asp718 (701) Asp718 (794) Acc65I (701) Acc65I (794)
701 CGGTACCTGGTCTCCACCTAGCTCCCTGCAGCTGGGACTGCTGTTAAACGGGGTCTGCAGCCTGGCTGAGGAGCTGCGCCACATCCACTCCAGGTACC
45 R Y L V L H L A S L Q L G L L L N G V C S L A E E L R H I H S R Y

Bsp120I (854)
801 GGGGACGACTACTGGAGGACTGTGCGGGCCTGCCTGGGCTGCCCCCTCCCGCTGGGGCCCTGTGTGCTGTCCATCTATTTCTACTACTCCCTCCCAAA
78 R G S Y W R T V R A C L G C P L R R G A L L L L S I Y F Y S L P N

SfiI (970) BglIII (995)
901 TGGGTGCGCCCGCCTTCACTTGGATGCTTGCCTCCTGGGCTCTCGCAGGCACTGAACATCCTCCTGGGCTCAAGGGCTGCCCCAGCTGAGATC
111 A V G P P F T W M L A L L G L S Q A L N I L L G L K G L A P A E I

NcoI (1035) EcoRV (1064)
1001 TCTGAGTGTGTGAAAAGGGAATTTCAACGTGGCCATGGGCTGGCATGTTATACATCGGATATCTGCGGCTGATCCTGCCAGAGCTCCAGGGCC
145 S A V C E K G N F N V A H G L A W S Y Y I G Y L R L I L P E L Q A

BstBI (1103)
1101 GGATTCGAACCTTACAATCAGCATTACAACAACCTGTACGGGGTGCAGTGAAGCAGCGGCTGTATAATCTCCTCCATTGGACTGTGGGGTGCCTGATAA
178 R I R T Y N Q H Y N N L L R G A V S Q R L Y N L L P L D C G V P D N

AgeI (1252)
1201 CCTGAGTATGGTACCCCAACATTCGCTTCTGGATAAACTGCCCCAGCAGACCGGTGACCGTGTGCTGGCATCAAGGATCGGGTTTACAGCAACAGCATC
211 L S M A D P N I R F L D K L P Q Q T G D R A G I K D R V Y S N S I
1301 TATGAGCTTCTGGAGAACGGGCGAGCGGGGCGGACCTGTGCTGGAGTACGCCACCCCTTGCAGACTTTGTTGCCATGTCACAATACAGCTCAAGTG
245 Y E L L E N G Q R A G T C V L E Y A T P L Q T L F A M S Q Y S Q A
1401 GCTTTAGCGGGAGGATAGGCTTGAGCAGGCCAACTCTTGC CGGACACTT GAGGACATCCTGGCAGATGCCCTGAGTCTCAGAACAACTGCCGCT
278 G F S R E D R L E Q A K L F C R T L E D I L A D A P E S Q N N C R L
1501 CATTGCCTACCAGGAACCTGCAGATGACAGCAGCTTCTCGCTGTCCAGGAGGTTCTCCGGCACCTGCGGCAGGAGGAAAAGGAAAGGTTACTGTGGG
311 I A Y Q E P A D D S S F S L S Q E V L R H L R Q E E K E E V T V G

BpuAI (1605) BbsI (1605)
1601 AGCTTGAAGACTCAGCGGTGCCAGTACCTCCACGATGTCCCAAGAGCCTGAGCTCCTCATCAGTGAATGGAAAAGCCCTCCCTCTCCGACGGATT
345 S L K T S A V P S T S T M S Q E P E L L I S G M E K P L P L R T D

MscI (1745) NheI (1739)
1701 ICTCTGAGACCCAGGGTACCAGGCCAGACCTCCAGTGTAGCTGGCCAGACATGATAAGATACATTGATGAGTTTGGACAAACCACAACCTAGAATGC
378 F S

HpaI (1877) MfeI (1888)
1801 AGTGAAAAAATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAACCATTATAAGCTGCAATAAAACAAGTTAACAAACAACATTGCATTCA

EcoRI (1973)
1901 TTTTATGTTTCAGGTTCCAGGGGAGGTGTGGGAGGTTTTTAAAGCAAGTAAACCTCTACAAATGGGTATGGAATTTAAAATACAGCATAGCAAAA
2001 TTTAACCTCAAATCAAGCTCTACTTGAATCCTTTTCTGAGGGATGAATAAGGCATAGGCATCAGGGGCTTTGCCAATGTGCATTAGCTGTTTGCAGC
2101 CTCACCTCTTTTATGAGTTTAAAGATATAGTGTATTTTCCCAAGGTTTGAAGTCTTCTTATTTTAAATGCACTGACCTCCACATTC

SspI (2212) SmaI (2226)
2201 CCTTTTTAGTAAAATATTAGAAATAATTAATACATCATTGCAATGAAATAAATGTTTTTATTAGGCAGAATCCAGATGCTCAAGGCCCTTCATAA

2301 TATCCCCAGTTTGTAGTTGACTTAGGGAACAAGGAACCTTAATAGAAATGGACAGCAAGAAAGCGAGCTTCTAGCTTTAGTTCCTGGTGTACTT
144 N R T Y K

2401 GAGGGGATGAGTTCCTCAATGGTGGTTTTGACCAGCTTGCATTCATCTCAATGAGCACAAGCAGTCAAGGATAGTCAGAGATGAGCTCTCTGCAC
135 L P I L E E I T T K V L K G N M E I L V F C D P A Y D S I L E R C

BstXI (2516)
2501 ATGCCACAGGGGCTGACCACCTGATGGATCTGTCCACCTCATCAGAGTAGGGGTGCCTGACAGCCCAATGGTGTCAAAGTCTTCTGCCGTTGTCTCA
101 M G C P S V V R I S R D V E D S Y P H R V A V I T D F D K Q G N S V

StuI (2651)
2601 CAGCAGACCAATGGCAATGGCTCAGCAGACAGTACCCTGCAATGTAGGCTCAATGTGGACAGCAGAGATGATCTCCCGAGTCTTGGTCTGAT
68 A S G I A I A E A C V T V R G I Y A E I H V A S I I E G T K T R I

BpuAI (2797)

BbsI (2797)

XmnI (2793)

2701 GGCCGCCCCGACATGGTGTGTTGTCCTCATAGAGCATGGTGATCTTCTCAGTGGCGACCTCCACCAGCTCCAGATCCTGCTGAGAGATGTTGAAGGTC
35 A A G V H H K N D E Y L M T I K E T A V E V L E L D Q Q S I N F T

BspHI (2801)

AseI (2859)

2801 TTCATGATGGCCCTCTATAGTGAGTCGTATTATACTATGCCGATATACTATGCCGATGATTAATTGTCAA AACAGCGTGGATGGCGTCTCCAGCTTATC
1 K M

2901 TGACGGTCACTAAACGAGCTCTGCTTATATAGACCTCCACCCTACACGCTACCGCCATTTCGCTCAATGGGGCGGAGTTGTTACGACATTTGGAA

SpeI (3014)

3001 AGTCCCGTTGATTTACTAGTCAAAACAACTCCATTGACGCTCAATGGGGTGGAGACTTGGAAATCCCCGTGAGTCAAACCGCTATCCACGCCATTGAT

SnaBI (3142)

3101 GTACTGCCAAAACCGCATCATCATGGTAATAGCGATGACTAATACGTAGATGACTGCCAAGTAGGAAAGTCCCATAAGGTCATGTACTGGGCATAATGC

NdeI (3247)

3201 CAGGCGGGCCATTTACCGTCATTGACGCTCAATAGGGGGCTACTTGGCATATGATACACTTGATGACTGCCAAGTGGGCGAGTTTACCGTAAATACTCCA

3301 CCCATTGACGCTCAATGAAAGTCCCTATTGGCGTACTATGGGAACATACGTCATTATTGACGCTCAATGGCGGGGTCGTTGGGCGTACGCCAGGCGG

PacI (3433)

SdaI (3425)

PciI (3443)

SbfI (3425)

BspLU11I (3443)

3401 GCCATTTACCGTAAGTTATGTAACGCCTGCAGGTTAATTAAGAACATGTGAGCAAAGGCCAGCAAAGGCCAGGAACCGTAAAAAGGCCGCTTGCTGG

3501 CGTTTTCCATAGGCTCCGCCCCCTGACGAGCATCACAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTT

3601 TCCCCCTGGAAGCTCCCTCGTGCCTCTCTGTTCCGACCTGCCGTTACCGGATACTGTCCGCTTTCTCCCTTCGGGAAGCGTGCCGCTTTCTCAT

ApaLI (3757)

3701 AGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTGCTCCAAGCTGGGCTGTGTGCACGAACCCCGTTCAGCCCGACCGCTGCGCCTTATCCG

3801 GTAACATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGC

3901 TACAGAGTCTTGAAGTGGTGCCTAACTACGGCTACACTAGAAGAACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGAAAAAGAGTT

4001 GGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGTGGTTTTTTTTGTTGCAAGCAGCAGATTACGCGCAGAAAAAAGGATCTCAAGAAGATC

EagI (4193)

PacI (4173) SmaI (4182) NotI (4192)

4101 CTTTGATCTTTTCTACGGGTCTGACGCTCAGTGGAACGAAACTCACGTTAAGGGATTTTGGTCATGGCTAGTTAATTAACATTTAAATCAGCGGCCGC

4201 AATAAAATATCTTTATTTTATTACATCTGTGTGGTTTTTTTGTGTGAATCGTAACATAACGCTCTCCATCAAAACAAAACGAAACAAAACAAAC

4301 TAGCAAAATAGGCTGTCCCAAGTCAAGTGCAGGTGCCAGAATTTCTCTATCGAA